PTJ
ALLO icon

Paul Tudor Jones’s Allogene Therapeutics ALLO Stock Holding History

Paul Tudor Jones’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-72,105
Closed -$176K – 3496
2026
Q1 		$176K Buy
72,105
+1,097
+2% +$2.2K ﹤0.01% 3399
2025
Q4 		$97.3K Hold
71,008
– – ﹤0.01% 3382
2025
Q3 		$88K Hold
71,008
– – ﹤0.01% 3265
2025
Q2 		$80.2K Hold
71,008
– – ﹤0.01% 3159
2025
Q1 		$104K Buy
+71,008
New +$134K ﹤0.01% 2940
2024
Q3 		– Sell
-71,340
Closed -$166K – 2665
2024
Q2 		$166K Sell
71,340
-412
-0.6% -$1.22K ﹤0.01% 2176
2024
Q1 		$321K Buy
+71,752
New +$299K ﹤0.01% 1827
2023
Q4 		– Sell
-73,998
Closed -$235K – 2328
2023
Q3 		$235K Buy
73,998
+63,135
+581% +$277K ﹤0.01% 2028
2023
Q2 		$54K Buy
+10,863
New +$58.8K ﹤0.01% 2322
2023
Q1 		– Sell
-77,228
Closed -$486K – 2361
2022
Q4 		$486K Buy
77,228
+60,175
+353% +$557K 0.01% 1597
2022
Q3 		$184K Buy
+17,053
New +$232K ﹤0.01% 2096
2022
Q2 		– Sell
-171,247
Closed -$1.56M – 2067
2022
Q1 		$1.56M Buy
171,247
+99,356
+138% +$1.03M 0.04% 672
2021
Q4 		$1.07M Buy
+71,891
New +$1.27M 0.02% 954
2021
Q3 		– Sell
-98,912
Closed -$2.58M – 2419
2021
Q2 		$2.58M Buy
+98,912
New +$2.82M 0.05% 459
2021
Q1 		– Sell
-12,120
Closed -$306K – 1534
2020
Q4 		$306K Buy
12,120
+1,197
+11% +$39K 0.01% 1113
2020
Q3 		$412K Sell
10,923
-39,476
-78% -$1.49M 0.02% 892
2020
Q2 		$2.16M Buy
+50,399
New +$1.82M 0.11% 229

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Paul Tudor Jones's ALLO Position: Q2 2026 in Review

Paul Tudor Jones sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 72,105 shares — an estimated $176K sold.

Paul Tudor Jones first reported a position in ALLO in Q2 2020 and held it in 17 quarters. The position peaked at $2.58M in Q2 2021. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Paul Tudor Jones reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 72,105 Allogene Therapeutics shares in Q2 2026, an estimated $176K.
  • Paul Tudor Jones first reported a position in Allogene Therapeutics in Q2 2020 and held it in 17 quarters.
  • Paul Tudor Jones's Allogene Therapeutics position peaked at $2.58M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.